Media headlines about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zimmer Biomet earned a news impact score of 0.21 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.5230073075334 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of equities research analysts have commented on ZBH shares. Zacks Investment Research upgraded Zimmer Biomet from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. SunTrust Banks restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet in a research report on Monday, October 2nd. Piper Jaffray Companies lowered Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 2nd. BMO Capital Markets decreased their price objective on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, November 2nd. Finally, Morgan Stanley decreased their price objective on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $137.42.
Shares of Zimmer Biomet (NYSE:ZBH) traded up $0.81 during mid-day trading on Wednesday, hitting $122.49. The company had a trading volume of 1,168,080 shares, compared to its average volume of 1,392,764. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet has a 1-year low of $108.03 and a 1-year high of $133.49. The company has a market cap of $24,830.00, a P/E ratio of 38.16, a price-to-earnings-growth ratio of 1.90 and a beta of 1.15.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, December 28th. Zimmer Biomet’s payout ratio is 29.91%.
COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet (NYSE:ZBH) Earns Media Sentiment Score of 0.21” was first published by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/zimmer-biomet-zbh-earning-somewhat-positive-media-coverage-report-finds/1823809.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.